🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesHas anyone dealt with a1c target achievement rates?

Has anyone dealt with a1c target achievement rates?

Dr.NephBHM_UK Mon, Jul 21, 2025 at 7:51 AM 9 replies 1,380 viewsPage 1 of 2
This thread is more than 10 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Jul 21, 2025 at 7:51 AM#1

A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

The question I want answered is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

Numbers rather than impressions, if you have them.

37 7Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 34 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Jul 21, 2025 at 9:11 AM#2
Dr.NephBHM_UK said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

36 6roxy_nash, tony_orlando, Dr.NephBHM_UK and 33 others
Reply Quote Save Share Report
LondonLisa
Member
912
3,456
Mar 2024
London, UK
Jul 21, 2025 at 10:31 AM#3
sarah.morrison said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 36% to 19%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

35 5RetaRick_CA, JenPlateau, SallyK_inj and 32 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Jul 21, 2025 at 11:51 AM#4
Dr.NephBHM_UK said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Can confirm. Same sequence, different timescale. I had assumed I was the exception until I read this.

34 4sophie_paris, mel_PDX, Dr.AddMedPHL and 31 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Jul 21, 2025 at 7:36 PM#5

Adding the clinical framing, because it changes how the question reads.

My labs after 6 months on glycaemic control: A1C 5.0%, fasting glucose 80 mg/dL, fasting insulin 7 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.5% and fasting glucose was 125 mg/dL. The improvement has been dramatic and consistent.

33 3bbq_ray_KC, oliver_london, tane_welly and 30 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register